SCHEMBL30925463

SCHEMBL30925463

CCn1ccnc1S(=O)(=O)Nc1cccc2cc(OC)cnc12

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 14/20 0.48
▸ GLO1 Q04760 2/20 0.48
▸ MEN1 O00255 5/20 0.46
▸ KMT2A Q03164 5/20 0.46
▸ TDP1 Q9NUW8 5/20 0.46
▸ CXCR2 P25025 2/20 0.44
▸ POLB P06746 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ AGTR1 P30556 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ CXCR4 P61073 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30925482 0.87 SLC40A1 (0.63) SLC40A1GLO1MEN1KMT2ATDP1
SCHEMBL26964402 0.86 SLC40A1 (0.60) SLC40A1GLO1MEN1KMT2ATDP1
SCHEMBL29800997 0.86 SLC40A1 (0.60) SLC40A1GLO1MEN1KMT2ATDP1
SCHEMBL27214237 0.85 SLC40A1 (0.45) SLC40A1GLO1
SCHEMBL30925557 0.85 SLC40A1 (0.47) SLC40A1MEN1KMT2ATDP1
SCHEMBL27214324 0.85 SLC40A1 (0.47) SLC40A1MEN1KMT2ATDP1
SCHEMBL30925508 0.85 SLC40A1 (0.45) SLC40A1GLO1
SCHEMBL29800797 0.84 SLC40A1 (0.44) SLC40A1GLO1MEN1KMT2ATDP1
SCHEMBL26964396 0.84 SLC40A1 (0.44) SLC40A1GLO1MEN1KMT2ATDP1
SCHEMBL29800780 0.83 SLC40A1 (0.43) SLC40A1GLO1MEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 SLC40A1 3357/4885GLO1 3779/4885MEN1 2604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback